Oteseconazole (VT-1161): Precision Antifungal Targeting for Candida Infections

Executive Summary: Oteseconazole (VT-1161) is a next-generation tetrazole antifungal agent that selectively inhibits fungal CYP51, blocking ergosterol synthesis and compromising fungal cell membrane integrity (J. Fungi 2022). It exhibits potent in vitro activity against multiple Candida species, with minimum inhibitory concentrations (MICs) as low as ≤0.00625 μg/mL, including efficacy against fluconazole-resistant isolates (product_spec). Oteseconazole's IC50 for human CYP3A4 is 65 μM, markedly reducing risk of adverse drug-drug interactions compared to older azoles (product_spec). Clinical utility includes oral administration for prevention of recurrent vulvovaginal candidiasis (RVVC) (J. Fungi 2022). The compound is available from APExBIO as BA1665, with recommended storage at -20°C and solutions for short-term use (product_spec).

Biological Rationale

Fungal infections caused by Candida species are a significant clinical concern, especially in immunocompromised patients. The growing prevalence of multidrug-resistant strains, notably Candida auris, has heightened the need for novel antifungal agents (J. Fungi 2022). Azole antifungals, while widely used, are limited by resistance, toxicity, and pharmacokinetic challenges. Oteseconazole (VT-1161) addresses these gaps by offering high selectivity for fungal CYP51 and robust activity against both common and resistant Candida species (product_spec).

Mechanism of Action of Oteseconazole (VT-1161)

Oteseconazole is a tetrazole derivative that targets lanosterol 14α-demethylase (CYP51), a key enzyme in the ergosterol biosynthesis pathway. By binding to CYP51, Oteseconazole blocks the demethylation step required for ergosterol production, resulting in defective fungal cell membranes and inhibited growth (J. Fungi 2022). Unlike imidazole and triazole antifungals, Oteseconazole demonstrates high selectivity for fungal CYP51 over human cytochrome P450 isoforms, notably with an IC50 of 65 μM for human CYP3A4 (product_spec). This minimizes off-target effects and reduces the likelihood of drug-drug interactions.

For an advanced discussion of Oteseconazole's selectivity and pharmacology, see this detailed review, which expands on CYP51 targeting and clinical implications.

Evidence & Benchmarks

• Oteseconazole exhibits potent in vitro antifungal activity against Candida albicans, C. tropicalis, C. parapsilosis, C. glabrata, C. krusei, and Cryptococcus neoformans, with MIC values ranging from ≤0.00625 to 0.1 μg/mL (source: product_spec).
• The compound demonstrates inactivity against Aspergillus fumigatus (MIC >64 μg/mL), confirming its spectrum is largely restricted to yeast-form fungi (source: product_spec).
• Oteseconazole retains efficacy against fluconazole-resistant Candida strains, including clinical isolates of C. auris (source: J. Fungi 2022).
• Human CYP3A4 IC50 is 65 μM, which is significantly higher (i.e., less potent) than its activity on fungal CYP51, indicating low risk of cytochrome-mediated drug interactions (source: product_spec).
• Typical in vitro testing concentrations are 0.00625–0.1 μg/mL for Candida species, matching clinical exposure levels (source: product_spec).
• Oral Oteseconazole is clinically approved for the prevention of recurrent vulvovaginal candidiasis (RVVC) (source: dossier).
• Oteseconazole is supplied as a solid, MW 527.39, soluble at ≥50 mg/mL in DMSO or ethanol, insoluble in water (source: product_spec).

This article extends the protocol-focused resource by offering updated evidence benchmarks and workflow integration best practices.

Applications, Limits & Misconceptions

Oteseconazole is indicated for research and clinical use in the prevention of recurrent vulvovaginal candidiasis and in studies targeting fluconazole-resistant Candida species (J. Fungi 2022). Its high selectivity profile enables combination with other therapeutics, provided there is no CYP3A4 substrate overlap. However, Oteseconazole is not active against filamentous fungi such as Aspergillus and should not be used for non-yeast fungal infections. For a mechanistic comparison and translational context, see this in-depth analysis, which details pharmacological nuances and research use cases.

Common Pitfalls or Misconceptions

• Oteseconazole is ineffective against Aspergillus fumigatus and molds (MIC >64 μg/mL); it should not be used for non-yeast fungal infections (source: product_spec).
• Despite high selectivity, co-administration with strong CYP3A4 inducers/inhibitors may still alter plasma levels; clinical monitoring remains necessary (source: workflow_recommendation).
• Oteseconazole solutions should be prepared fresh and used short-term to maintain compound stability; avoid extended storage at room temperature (source: product_spec).
• It is not a substitute for echinocandins in treating invasive or bloodstream candidiasis caused by C. auris, although it shows promising in vitro activity (source: J. Fungi 2022).
• Oteseconazole should not be used in water-based formulations due to insolubility; DMSO or ethanol are preferred solvents (source: product_spec).

Workflow Integration & Parameters

Protocol Parameters

• assay | 0.00625–0.1 μg/mL | In vitro MIC for Candida spp. | Matches clinical steady-state levels and published antifungal benchmarks | product_spec
• assay | ≥50 mg/mL in DMSO or ethanol | Stock solution preparation | Ensures maximal solubility for accurate dosing in assays | product_spec
• assay | -20°C | Solid storage | Maintains compound stability and prevents degradation | product_spec
• assay | Short-term (≤1 week) at 4°C (solution) | Solution use window | Minimizes risk of compound breakdown and loss of potency | product_spec
• assay | IC50 (human CYP3A4) = 65 μM | Safety margin assessment | Establishes low risk for human CYP inhibition | product_spec

Conclusion & Outlook

Oteseconazole (VT-1161) represents a significant advance in antifungal therapy, offering high potency, selectivity, and a favorable safety profile for managing Candida infections, including fluconazole-resistant isolates (J. Fungi 2022). Its clinical application in RVVC and compatibility with modern antifungal susceptibility workflows make it a preferred research compound. Ongoing surveillance for resistance and real-world outcome studies are warranted, but current data support Oteseconazole as a next-generation standard for targeted antifungal strategies (APExBIO).